RKDA — Arcadia Biosciences, Inc.

Summary of Arcadia Biosciences, Inc. Q1 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Approximately $1.2 million, a 22% increase year-over-year.
• Zola Revenue: Grew 90% year-over-year, driven by a 70% increase in new distribution.
• Gross Margin: 43%, down from 52% in Q1 2024; however, this marks the ninth consecutive quarter with gross margins above 30%.
• Operating Expenses: Reduced by 16% year-over-year, totaling $1.7 million, which includes nearly $500,000 in transaction-related fees.
• Cash Position: Ended Q1 with $3.2 million in cash, down from $4.2 million at the beginning of the year.
• Accounts Receivable: Increased to $1.6 million, reflecting cash from patent sales and recovery of previously reserved receivables.
• Inventory: Grew to $1.3 million, preparing for the spring-summer selling season.

2. Strategic Updates and Business Highlights

• Zola Coconut Water: Continued strong performance with significant distribution gains and new product innovations, including successful new flavors.
• Intellectual Property Monetization: Completed a transaction with BioSeries, regaining rights to certain soy patents and eliminating a $1 million contingent liability.
• Business Combination with Roosevelt Resources: Progressing towards completion by August 2025, with a fixed equity share ratio of 90-10 for stockholders, enhancing ownership certainty.

3. Forward Guidance and Outlook

• Anticipate continued revenue growth from Zola, with new customer accounts expected to contribute positively in 2025.
• No significant impact from recent tariffs expected due to proactive inventory management and cost-saving measures.
• The company is optimistic about launching new product innovations early next year.

4. Bad News, Challenges, or Points of Concern

• Gross Margin Decline: The drop from 52% to 43% raises concerns about cost management as the company transitions to a single product line.
• Legacy Business Exit: While progress has been made, the remaining tomato patent still represents a contingent liability, and its future commercialization is uncertain.
• Pending Business Combination Risks: The timeline for the Roosevelt Resources transaction has been extended, introducing uncertainties regarding completion and integration.

5. Notable Q&A Insights

• Distribution Pipeline: Approximately 50% of current distribution is in discussions for expansion, with new accounts already secured for Q2.
• Commercial Value of Legacy Patent: The remaining tomato patent may have potential value, but it is licensed to a third party, delaying any benefits to Arcadia.
• Note Receivable: A $2.5 million payment from the sale of GoodWheat assets is expected in Q2, which will bolster cash reserves.

Overall, Arcadia Biosciences demonstrated strong growth in its Zola brand while making significant strides in exiting its legacy AgTech business, though challenges remain in maintaining margins and completing the Roosevelt transaction.